Waldencast plc (NASDAQ:WALD) Forecasted to Post FY2022 Earnings of $0.02 Per Share

Waldencast plc (NASDAQ:WALD – Get Rating) – Stock analysts at Telsey Advisory Group issued their FY2022 EPS estimates for shares of Waldencast in a report issued on Thursday, March 9th. Telsey Advisory Group analyst D. Telsey forecasts that the company will earn $0.02 per share for the year. Telsey Advisory Group currently has a “Outperform” rating and a $13.00 price target on the stock. The consensus estimate for Waldencast’s current full-year earnings is $0.05 per share. Telsey Advisory Group also issued estimates for Waldencast’s Q4 2022 earnings at ($0.03) EPS and FY2023 earnings at $0.23 EPS.

Separately, DA Davidson raised their target price on shares of Waldencast from $12.00 to $15.50 and gave the company a “buy” rating in a research note on Thursday, November 17th.

Waldencast Trading Up 4.4 %

Waldencast stock opened at $7.84 on Monday. The firm’s 50 day moving average price is $8.68 and its two-hundred day moving average price is $8.97. Waldencast has a twelve month low of $6.56 and a twelve month high of $12.10.

Institutional Trading of Waldencast

Hedge funds have recently bought and sold shares of the stock. Westchester Capital Management LLC bought a new stake in Waldencast in the 2nd quarter valued at $5,257,000. RPO LLC increased its stake in Waldencast by 865.6% in the second quarter. RPO LLC now owns 619,443 shares of the company’s stock valued at $6,101,000 after acquiring an additional 555,292 shares during the period. Truxt Investmentos Ltda. acquired a new position in Waldencast in the third quarter worth about $50,000,000. Exos Asset Management LLC bought a new position in Waldencast during the second quarter worth about $347,000. Finally, Sculptor Capital LP boosted its holdings in Waldencast by 160.8% during the second quarter. Sculptor Capital LP now owns 3,092,804 shares of the company’s stock valued at $30,464,000 after purchasing an additional 1,906,998 shares in the last quarter. 18.80% of the stock is owned by institutional investors.

About Waldencast

(Get Rating)

Waldencast plc, a skincare company, develops, markets, and sells skin health products worldwide. The company offers approximately 200 cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.